ATE403438T1 - Immuntherapeutische kombinationen zur tumorbehandlung - Google Patents

Immuntherapeutische kombinationen zur tumorbehandlung

Info

Publication number
ATE403438T1
ATE403438T1 AT01999388T AT01999388T ATE403438T1 AT E403438 T1 ATE403438 T1 AT E403438T1 AT 01999388 T AT01999388 T AT 01999388T AT 01999388 T AT01999388 T AT 01999388T AT E403438 T1 ATE403438 T1 AT E403438T1
Authority
AT
Austria
Prior art keywords
tumor treatment
immunotherapeutic combinations
immunotherapeutic
combinations
tumor
Prior art date
Application number
AT01999388T
Other languages
English (en)
Inventor
Rodriguez Rolando Perez
Marinello Gisela Gonzalez
Ramos Tania Crombet
Delgado Irene Beausoleil
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of ATE403438T1 publication Critical patent/ATE403438T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01999388T 2000-12-08 2001-12-06 Immuntherapeutische kombinationen zur tumorbehandlung ATE403438T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina

Publications (1)

Publication Number Publication Date
ATE403438T1 true ATE403438T1 (de) 2008-08-15

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01999388T ATE403438T1 (de) 2000-12-08 2001-12-06 Immuntherapeutische kombinationen zur tumorbehandlung

Country Status (25)

Country Link
US (2) US20020160014A1 (de)
EP (2) EP1350521B1 (de)
JP (2) JP2005519023A (de)
KR (1) KR20030064416A (de)
CN (1) CN1326566C (de)
AR (1) AR031641A1 (de)
AT (1) ATE403438T1 (de)
AU (2) AU2002221521B2 (de)
BR (1) BR0116010A (de)
CA (1) CA2431199C (de)
CU (1) CU22979A1 (de)
CY (1) CY1108474T1 (de)
DE (1) DE60135248D1 (de)
DK (1) DK1350521T3 (de)
EA (1) EA007381B1 (de)
ES (1) ES2311036T3 (de)
MX (1) MXPA03005030A (de)
MY (1) MY138833A (de)
NZ (1) NZ526284A (de)
PE (1) PE20020695A1 (de)
PT (1) PT1350521E (de)
SI (1) SI1350521T1 (de)
UY (1) UY27058A1 (de)
WO (1) WO2002045747A1 (de)
ZA (1) ZA200304415B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (de) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibierung von Stress-induzierter Liganden-abhängiger EGFR Aktivierung
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
RU2537245C2 (ru) * 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
JP5420568B2 (ja) 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
EP2436397B1 (de) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
WO2018151811A2 (en) 2017-02-17 2018-08-23 George Todaro Use of tgf alpha for the treatment of diseases and disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP0586002B1 (de) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
EP0657175B1 (de) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Impfstoff, der einen menschlichen autologenen epidermalen Wachstumsfaktor enthält und dessen Verwendung
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6548066B1 (en) * 1997-05-12 2003-04-15 Aphton Corporation Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
WO1999057981A1 (en) * 1998-05-08 1999-11-18 Sloan-Kettering Institute For Cancer Research Compositions and methods for active vaccination
AU4079999A (en) * 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6783761B2 (en) * 2000-05-05 2004-08-31 Aphton Corporation Chimeric peptide immunogens
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
EA007381B1 (ru) 2006-10-27
JP2005519023A (ja) 2005-06-30
PT1350521E (pt) 2008-11-14
CN1326566C (zh) 2007-07-18
CN1592636A (zh) 2005-03-09
DK1350521T3 (da) 2008-11-10
PE20020695A1 (es) 2002-09-23
US7744871B2 (en) 2010-06-29
CU22979A1 (es) 2004-09-09
SI1350521T1 (sl) 2008-12-31
EA200300646A1 (ru) 2003-10-30
EP2005996A2 (de) 2008-12-24
EP1350521A1 (de) 2003-10-08
KR20030064416A (ko) 2003-07-31
ES2311036T3 (es) 2009-02-01
US20060188497A1 (en) 2006-08-24
MY138833A (en) 2009-07-31
UY27058A1 (es) 2002-03-22
ZA200304415B (en) 2004-07-07
AU2002221521B2 (en) 2007-01-04
CA2431199C (en) 2011-10-04
US20020160014A1 (en) 2002-10-31
CA2431199A1 (en) 2002-06-13
MXPA03005030A (es) 2004-09-10
DE60135248D1 (de) 2008-09-18
CY1108474T1 (el) 2014-04-09
EP1350521B1 (de) 2008-08-06
AU2152102A (en) 2002-06-18
WO2002045747A1 (es) 2002-06-13
EP2005996A3 (de) 2012-01-25
JP2010150286A (ja) 2010-07-08
BR0116010A (pt) 2004-01-06
NZ526284A (en) 2004-11-26
AR031641A1 (es) 2003-09-24
HK1073244A1 (zh) 2005-09-30

Similar Documents

Publication Publication Date Title
KR100695846B9 (ko) 암 치료
ATE430570T1 (de) Synergistische kombinationstherapie zur krebsbehandlung
DE60142565D1 (de) Mittel zur wasserbehandlung
NO20035156L (no) Fremgangsmåter for brønnbehandling
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DK1267650T3 (da) Tobakbehandling
DE60313021D1 (de) 4-tetrazolyl-4-phenylpiperidindervate zur schmerzbehandlung
ATE342101T1 (de) Gerillte quellen zur brachytherapie
EP1446129A4 (de) Polynucleotid-therapie
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
DE50106015D1 (de) Osteosynthesemittel
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
NO20032122L (no) Forbedret behandling
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
DE60135248D1 (de) Immuntherapeutische kombinationen zur tumorbehandlung
DE60227963D1 (de) Behandlungssystem
ATE297914T1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid- derivate zur schmerzbehandlung
AU2002221521A1 (en) Immunotherapeutic combinations for the treatment of tumors
DE60212843D1 (de) Mandrin
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
DE60005566D1 (de) Pyranoindole zur glaukombehandlung
ID30377A (id) Metoda pengobatan neurodegenerasi
DE10290185D2 (de) Tumorvakzine
GB0026015D0 (en) Cancer treatment
GB0130763D0 (en) Treatment methods

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1350521

Country of ref document: EP